Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
Rakesh
R
Popat
Lenushka
L
Maharaj
Heather
H
Oakervee
Jamie
J
Cavenagh
Simon
S
Joel
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan